University of Colorado Health

Quarterly bond compliance packet

For the quarter ending December 31, 2023





Note: Per GASB reporting requirements, all FY24 financial and operating data includes Parkview Health System (acquired on 12/1/23) on a full YTD basis for FY24, For reporting purposes, Parkview is included in the metrics for the South Region.

Unaudited Results University of Colorado Health Comparative Summary Statements of Income & Changes in Fund Balances ³



For the Period Ended December 31, 2023 (in Thousands)

	Quarter 2 Obligated System				Obligated	ear-to-Date System		
	Gr	oup Total ²	Cc	onsolidated	Gr	oup Total 2	Co	onsolidated
Operating Revenue								
Net Patient Revenue 1	\$	1,947,794	\$	1,977,483	\$	3,829,028	\$	3,885,245
Grant Revenue		1,696		2,136		3,696		4,543
Other Operating Revenue		36,741		37,656		41,206		44,518
Total Net Operating Revenue	\$	1,986,231	\$	2,017,274	\$	3,873,931	\$	3,934,306
Operating Expenses:								
Wages, Contract labor, & benefits	\$	892,616	\$	902,747	\$	1,759,998	\$	1,778,998
Supplies	·	481,538	·	490,551	·	938,224	·	954,313
Purchased Services & Other Expenses		384,020		397,681		757,482		785,790
Depreciation and Amortization		114,470		116,281		226,426		230,199
Total Operating Expense	\$	1,872,644	\$	1,907,259	\$	3,682,129	\$	3,749,301
Operating Income (Loss)	\$	113,588	\$	110,015	\$	191,801	\$	185,005
Nonoperating revenue & expenses								
Interest Expense	\$	(10,296)	\$	(10,780)	\$	(20,243)	\$	(21,175)
Investment Income	,	433,383	•	441,018	•	340,793	•	345,857
Other Non-Operating Revenue		(12,889)		(13,023)		(23,779)		(24,488)
Gain (Loss) Disposal Cap		254		433		553		732
Total Nonoperating Income	\$	410,452	\$	417,649	\$	297,323	\$	300,927
Income Before Contributions	\$	524,040	\$	527,664	\$	489,124	\$	485,931
Non-Recurring	\$	-	\$	-	\$	-	\$	-
Restricted contributions	-	(1)	-	2,009		1,061	-	4,056
Distribution of Net Assets		-		-		-		- -
Increase (Decrease) in Net Assets	\$	524,039	\$	529,673	\$	490,185	\$	489,988

Unaudited Results
University of Colorado Health
Comparative Summary Statements of
Income & Changes in Fund Balances ³



For the Period Ended December 31, 2022 (Prior Year) (in Thousands)

	Quarter 2				Fiscal Year-to-Date					
		Obligated		System		Obligated	System			
	Gr	Group Total ²		Consolidated		oup Total 2	Consolidated			
Operating Revenue										
Net Patient Revenue 1	\$	1,677,101	\$	1,697,741	\$	3,277,717	\$	3,317,656		
Grant Revenue		1,283		1,610		2,077		2,706		
Other Operating Revenue		19,601		24,340		39,960		48,923		
Total Net Operating Revenue	\$	1,697,986	\$	1,723,692	\$	3,319,753	\$	3,369,285		
Operating Expenses:										
Wages, Contract labor, & benefits	\$	787,805	\$	797,799	\$	1,525,405	\$	1,544,046		
Supplies	Ψ	413,856	Ψ	420,629	Ψ	818,268	Ψ	831,349		
Purchased Services & Other Expenses		338,374		351,356		664,765		690,660		
Depreciation and Amortization		81,449		83,200		163,467		167,071		
Total Operating Expense	\$	1,621,484	\$	1,652,985	\$	3,171,905	\$	3,233,125		
Operating Income (Loss)	<u>\$</u>	76,502	\$	70,707	\$	147,849	\$	136,159		
oporating mooms (2000)	Ť	. 0,002		10,101	<u> </u>	,		100,100		
Nonoperating revenue & expenses										
Interest Expense	\$	(7,699)	\$	(8,087)	\$	(16,404)	\$	(17,204)		
Investment Income		302,981		307,952		103,054		103,896		
Other Non-Operating Revenue		(7,951)		(7,726)		(17,515)		(17,887)		
Gain (Loss) Disposal Cap		(35)		(35)		34		34		
Total Nonoperating Income	\$	287,296	\$	292,104	\$	69,169	\$	68,839		
Income Before Contributions	\$	363,798	\$	362,811	\$	217,018	\$	204,998		
Non-Recurring	\$	_	\$	_	\$	_	\$	_		
Restricted contributions	Ψ	18	Ψ	857	Ψ	101	Ψ	1,210		
Distribution of Net Assets		(744)		(744)		(744)		(744)		
Increase (Decrease) in Net Assets	\$	363,072	\$	362,924	\$	216,375	\$	205,464		

Unaudited Results University of Colorado Health Comparative Balance Sheet ³ (in Thousands) December 31, 2023

uchealth

December 31, 2023									
		December 31, 2023			December 31, 2022				
		Obligated		System		Obligated		System	
		Group ¹	C	onsolidated		Group ¹	C.	onsolidated	
Current assets	•	050 005	•	000.400	•	005.544	•	000 040	
Cash and cash equivalents	\$	256,697	\$	266,106	\$	205,541	\$	226,016	
Patient accounts receivable, less allowances for uncollectible accounts		760,118		770,234		679,285		685,689	
Other receivables		166,555		95,341		164,972		79,738	
Inventories		147,474		157,036		127,385		139,098	
Prepaid expenses		129,656		130,060		95,990		98,964	
Investments designated for liquidity support	_	203,600	_	203,600	_	219,755	_	219,755	
Total current assets	\$	1,664,100	\$	1,622,377	\$	1,492,928	\$	1,449,261	
Non-current assets									
Restricted investments, bonds	\$	2,905	\$	2,905	\$	0	\$	0	
Restricted investments, other		399		399		470		470	
Restricted investments and donor pledges		18,093		78,361		16,108		61,824	
Capital assets, net of accumulated depreciation and amortization		4,348,487		4,367,542		3,734,698		3,758,370	
Long-term investments		2,552,320		2,606,173		1,935,331		1,977,225	
Assets designated for long-term purposes		3,180,108		3,180,108		2,976,244		2,976,244	
Other investments		110,365		110,360		95,344		101,312	
Other assets		88,778		88,920		97,369		97,509	
Deferred outflows of resources		169,473		169,886		181,482		182,222	
Total non-current assets	\$	10,470,927	\$	10,604,652	\$	9,037,047	\$	9,155,176	
Total assets	\$	12,135,027	\$	12,227,029	\$	10,529,974	\$	10,604,437	
Current liabilities									
Current portion of long-term debt	\$	120,484	\$	120,946	\$	106,587	\$	107,127	
Accounts payable and accrued expenses		1,117,312		319,821		688,504		703,510	
Accounts payable - construction		48,656		48,656		50,964		50,964	
Accrued compensated absences		142,952		144,303		123,710		125,144	
Accrued interest payable		6,200		6,200		3,715		3,715	
Fair value of derivative instruments		, <u>-</u>		-		, -		· -	
Estimated third-party settlements		194,420		194,420		215,497		215,497	
Long-term debt subject to short-term remarketing arrangements		203,600		203,600		219,755		219,755	
Total current liabilities	\$	1,833,624	\$	1,037,946	\$	1,408,733	\$	1,425,712	
Long-term liabilities									
Long-term debt, less current portion	\$	1,595,276	\$	1,598,232	\$	1,394,802	\$	1,398,480	
Fair value of derivative instruments, less current portion	Ψ	1,333,270	Ψ	0	Ψ	0	Ψ	0	
Other long-term liabilities		313,749		313,825		303,523		304,695	
Deferred inflows of resources		67,200		67,200		75,927		75,927	
Total long-term liabilities	\$	1,976,225	\$	1,979,257	\$	1,774,252	\$	1,779,103	
Total fund balance	\$	8,325,177		9,209,826	\$	7,346,990	\$	7,399,623	
Total liabilities and fund balance (unrestricted funds)	\$		\$		\$		\$		
rotal habilities and fund balance (unrestricted funds)	<u> </u>	12,135,027	Þ	12,227,029	Þ	10,529,974	Ф	10,604,437	



(in Thousands)				
		Quarter 2	Y	Fiscal ear-to-Date
	Co	System Insolidated	Co	System onsolidated
Cash flows from operating activities				
Cash received from patients and third-party payors	\$	2,128,791	\$	3,884,220
Cash payments to suppliers for goods and services		(997,281)		(1,787,983)
Cash payments to employees/other on behalf of employees		(982,808)		(1,702,871)
Other cash payments		(15,038)		(21,509)
Other cash received		29,838		43,381
Net cash provided by operating activities		163,502	-	415,238
Cash flows from capital and related financing activities Proceeds from long-term debt		-		-
Principal payments under lease and right to use obligations		(95,943)		(56,204)
Principal repayments of long-term debt		(97,417)		(97,417)
Payments of interest and issuance costs on long-term debt		(20,872)		(25,176)
Capital expenditures		(64,079)		(251,916)
Cash acquired from component unit		24,805		24,805
Receipt of contributions (Distributions to) contributions from minority interest in component unit		2,030		4,086
(Distributions to) contributions from minority interest in component unit Proceeds from sale of capital assets		(1,060) 988		(46,626) 1,018
Net cash used in capital and related financing activities		(251,548)		(447,430)
Cash flows from noncapital financing activities		(===,===)		(***,****)
Receipt of grant revenue		-		-
Net cash provided by noncapital financing activities		-		
Cash flows from Investing activities Investment income		150 460		104 042
Distributions received from joint ventures		150,462 2,593		184,843 4,799
Loans repaid by third parties		2,593 352		4,799 785
Proceeds from sale and maturities of investments		1,394,137		2,232,860
Purchases of investments		(1,436,710)		(2,318,009)
Net cash used in investing activities		110,834		105,278
Net increase (decrease) in cash and cash equivalents		22,788		73,086
Cash and cash equivalents at beginning of period		243,318		193,020
Cash and cash equivalents at end of period	\$	266,106	\$	266,106
Reconciliation of operating income to net cash provided by operating activities:				
Operating income	\$	91,071	\$	185,005
Adjustments to reconcile operating income to net cash provided by operating activities		400 500		000.400
Depreciation and amortization		122,586		230,199
Provision for bad debts		130,804		235,290
Decrease (increase) in patient accounts receivable Increase (decrease) in estimated third-party settlements		(171,228) 14,794		(310,690) 26,820
Decrease (increase) in other receivables and receivables from related parties		5,475		1,147
Decrease (increase) in inventories		(11,013)		(11,621)
Change in net pension assets/liabilities		8,940		12,223
Decrease (increase) in prepaid expenses		(9,763)		(23,181)
Decrease (increase) in other assets		2,567		7,363
Increase (decrease) in accounts payable and accrued expenses		(40,584)		61,737
Increase (decrease) in accrued compensated absences and other		17,929		12,391
Equity income from joint ventures		1,618		2,456
Acquired assets and liabilities from component unit		9,092		9,092
Adjustments to other cash receipts/payments		(8,786)		(22,993)
Total adjustments		72,431		230,233
Net cash provided by operating activities	\$	163,502	\$	415,238
Non-cash transactions:				
Donated pharmaceuticals	\$	2,002	\$	4,063
Construction in progress accrued	\$	48,656	\$	48,656
Non-cash capital purchase	\$	- 330 01 <i>E</i>	\$	102 502
Unrealized gain (loss) Refunding of debt	\$ \$	330,815	\$ \$	192,503
Unrealized gain (loss) on derivative instruments	\$	(19,416)	\$	(573)
Leases executed/cancelled	\$	116,423	\$	116,423

Unaudited Results University of Colorado Health Financial Covenant Calculations December 31, 2023 (in Thousands)	uche	ealth
Days Cash on Hand (fiscal year-to-date) Cash Investments Designated for Liquidity Support Assets Designated for Long-Term Purposes Long-Term Investments Total Cash and Investments	\$	256,697 203,600 3,180,108 2,552,320 6,192,724
Operating Expenses* Bad Debt Expense Interest Expense* Total Expenses	\$	3,802,468 235,290 16,417 4,054,176
Less: Depreciation/Amortization* Total Days	\$	181,789 3,872,387
Average Daily Operating Expense	\$	21,277
Days Cash on Hand		291.1
Indebtedness Ratio Long Term and Short Term Debt* Unrestricted Net Assets* Total Capitalization	\$ \$	1,481,919 9,117,824 10,599,742
Ratio of LT Debt to Total		14.0%
Debt Service Coverage Ratios (previous twelve month Income (loss) before Contributions & Impairment Add Back:	s)	1,119,980
Depreciation* Interest Expense* Unrealized (Gain)/Loss on Investments (Gain)/ Loss on Disposal of Capital Assets Income Available for Debt Service	\$ \$	409,105 31,964 614,111 7,299 939,639
Maximum Annual Debt Service*(1)	\$	100,477
MADS Coverage*		9.35

*Ratios and financial metrics are adjusted to exclude the impact of GASB 87/94/96. (1) Maximum Annual Debt Service as calculated per 2019A Official Statement Debt Service Schedule.



- In accordance with GASB 34, bad debt expense is classified as a reduction of net patient service revenue.
- ² Obligated group members include: University of Colorado Health, University of Colorado Hospital Authority, Poudre Valley Health Care, Inc., Medical Center of the Rockies, Longs Peak Hospital, Yampa Valley Medical Center, and Poudre Valley Medical Group LLC, UCHealth Broomfield Hospital, UCHealth Grandview Hospital, UCHealth Pikes Peak Regional Hospital, UCHealth Highlands Ranch Hospital, UCHealth Greeley Hospital, UCHealth Community Services, Parkview Health System, Parkview Medical Center, Inc., and Parkview Auxillary Services LLC
- ³ <u>GASB issued Statements</u> -The adoption of GASB 87, 94, 96 issued statements impacts the Statement of Income & Changes in Fund Balances, Balance Sheet, and Statement of Cash Flows, but not the Financial Covenant Calculations.
 - -- In 2017, the GASB issued Statement No. 87, Leases, which improves the accounting and financial reporting for leases by governments for the financial statement users. GASB Statement No. 87 increases the usefulness of governments' financial statements by requiring recognition of certain lease assets and liabilities for leases that previously were classified as operating leases and recognized as inflows of resources or outflows of resources based on the payment provisions of the contract. It establishes a single model for lease accounting based on the foundational principle that leases are financings of the right to use an underlying asset. Under GASB Statement No. 87, a lessee is required to recognize a lease liability and an intangible right-to-use lease asset, and a lessor is required to recognize a lease receivable and a deferred inflow of resources, thereby enhancing the relevance and consistency of information about governments' leasing activities. UCHealth adopted this statement effective July 1, 2020. The adoption impacted the combined balance sheet by adding right of use assets of \$333,016,287 and corresponding lease liability of \$213,248,065 as of the date of adoption. This adoption impacts the Statement of Income & Changes in Fund Balances, Balance Sheet, Statement of Cash Flows, but not the Financial Covenant Calculations.
 - -- In March 2020, the GASB issued Statement No. 94, Public-Private and Public-Public Partnerships and Availability Payment Arrangements, which improves accounting and financial reporting for arrangements where a governmental entity contracts with an operator to provide public services by conveying control of the right to operate or use nonfinancial assets, such as infrastructure or other capital assets, for a period of time in an exchange or exchange-like transaction. It establishes the definitions of public-private and public-public partnerships (PPP's) and availability payment arrangements (APA's) and provides uniform guidance on accounting and financial reporting for transactions that meet those definitions. It requires governments to report assets and liabilities related to PPP's consistently and disclose important information about PPP transactions. The provisions of this statement are effective for UCHealth's financial statements for the year ending June 30, 2023. This adoption impacts the Statement of Income & Changes in Fund Balances, Balance Sheet, and Statement of Cash Flows, but not the Financial Covenant Calculations.
 - -- In May 2020, the GASB issued Statement No. 96, Subscription-Based Information Technology Arrangements (SBITAs), which defines SBITAs and provides accounting and financial reporting for SBITAs by governments. This statement requires a government to recognize a subscription liability and an intangible right-to-use subscription asset for SBITAs. The provisions of this statement are effective for the Health System's financial statements for the year ending June 30, 2023. This adoption impacts the Statement of Income & Changes in Fund Balances, Balance Sheet, and Statement of Cash Flows, but not the Financial Covenant Calculations.
- ⁴ Parkview Health System (acquired on 12/1/23) included on a YTD basis for FY24, as part of South Region

